Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Coegin Pharma AB: BioStock: Coegin Pharma seeks new opportunities through merger

Coegin Pharma
Read the release

Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseae, is grabbing the opportunity to strengthen its drug development portfolio by putting strong focus on diabetes complications. BioStock was able to get in touch with Professors Anna Hultgårdh and Jan Nilsson, two internationally-recognised experts in diabetes complications to learn more about what the acquisition will mean for Coegin going forward.

Read the interview with Professors Anna Hultgårdh and Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/03/coegin-pharma-seeks-new-opportunities-through-merger/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.